Compare Organon & Co. Common Stock (OGN) vs Ferrari NV (RACE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs Ferrari NV — how do they compare? Organon & Co. Common Stock trades at $13.58 (market cap $3.62B), while Ferrari NV trades at $387.88 (market cap $68.73B). The key difference: Ferrari NV is far larger — about 19× Organon & Co. Common Stock's market cap, and Ferrari NV pays the higher dividend (1.08%). Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and Ferrari NV for 126 Days on average.
| OGN | RACE | |
|---|---|---|
Market Cap | $3.62B | $68.73B |
Volume | 2,892,999 | 283,474 |
Sector | Health | Consumer Cyclical |
52-Week High | $13.81 | $436.54 |
52-Week Low | $5.70 | $314.63 |
Typical Hold Time | 0 Days | 126 Days |
Enterprise Value | $11.04B | $70.60B |
Dividend Yield | 0.58% | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Ferrari (RACE) trades at $387.35, down 0.49% on the day, amid a bearish technical signal. The company demonstrates strong fundamentals with revenue growth from $7.15B in 2025 to a projected $7.4B in 2026 and a net income margin of 22.25%. Recent earnings beats and a share buyback program highlight operational strength. Analyst consensus is bullish with a $462.75 price target, though technical indicators show near-term pressure with support at $384.
The outlook remains positive given Ferrari's premium brand and consistent profitability, but high valuation multiples (P/E 37.67) and economic sensitivity pose risks. Institutional buying and bullish analyst ratings support upside potential, yet investors should monitor competitive pressures and macroeconomic headwinds that could impact luxury demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About Ferrari NV
Ferrari engineers and manufactures some of the world's most expensive exotic sports cars. The Ferrari brand is synonymous with Formula One racing, exclusivity, Italian design, and state-of-the-art technology. Ferrari also has a captive finance company that provides funding for dealers and clients.
Read more on RACE →
